The honest answers to your GLP-1 questions, all in one place.

The GLP-1 news worth knowing from the past week — ranked by what actually matters, so you can catch up in a minute.

1. 1
   Clinical

   GLP-1 Use Linked to Small Increase in Rare Optic Nerve Condition, Rutgers Study Finds

   A Rutgers analysis published in Annals of Internal Medicine found that adults with type 2 diabetes taking GLP-1 medications had a slightly higher rate of ischemic optic neuropathy, a rare drop in blood flow to the optic nerve that can cause sudden and often permanent vision loss. The absolute increase was small, roughly three to four extra cases per 10,000 patients over 18 months, and most affected patients were men or adults aged 50 to 65. Researchers caution the link may reflect underlying health differences rather than the drugs themselves, but say sudden vision changes warrant prompt evaluation by an eye specialist.

   SciTechDailyRead the original at SciTechDaily (opens in a new tab)
2. 2
   Market

   Italy's Menarini Licenses European Rights to Chinese GLP-1 Drug Bofanglutide

   Italy's Menarini Group signed an exclusive license agreement with China's Gan & Lee Pharmaceuticals for European rights to bofanglutide, a once-every-two-weeks GLP-1 receptor agonist for obesity and overweight. The deal is worth up to 726 million euros, including a 62 million euro upfront payment plus milestones, and covers 39 European markets including the EU, UK, and Switzerland.

   Endpoints NewsRead the original at Endpoints News (opens in a new tab)
3. 3
   Research

   GLP-1 Prescriptions for Children Under 12 With Obesity Up 310-Fold Since 2019, Still Rare

   An NYU Langone Health study published in Pediatrics found that prescriptions for Saxenda, Wegovy and Zepbound among U.S. children under 12 with obesity were 310 times higher in June 2026 than in 2019, though still only 0.6% of that group receive them, compared with 0.9% of adolescents ages 12 to 17. The numbers show pediatric use of these drugs is growing fast from a very small base at a time when long-term safety data in young children remains thin. Expect more scrutiny of prescribing guidelines as the trend continues.

   Medical XpressRead the original at Medical Xpress (opens in a new tab)
4. 4
   Insurance

   Analyst Sees Blockbuster Lilly Sales From Medicare's $50-a-Month GLP-1 Bridge Program

   Early uptake figures are in for Medicare's new "bridge" model, which offers weight-loss drugs to eligible seniors at $50 per month under the pricing deal the Trump administration struck with Eli Lilly and Novo Nordisk, and one analyst projects the program could translate into blockbuster annual sales for Lilly. For older adults, this is the first broad Medicare pathway to Wegovy and Zepbound for obesity itself rather than a related condition. How many seniors ultimately enroll, and how the program is funded long term, are still open questions.

   Fierce PharmaRead the original at Fierce Pharma (opens in a new tab)
5. 5
   Regulatory

   Connecticut AG Reaches Settlement With Online Platform Over Bootleg GLP-1 Sales

   Connecticut Attorney General William Tong announced a settlement with the international trade platform Made-in-China requiring it to stop hosting sellers of unapproved "research grade" semaglutide and tirzepatide to U.S. customers, with a penalty of up to $300,000 that is suspended after $30,000 if the company complies. The platform must now screen for and remove GLP-1 listings within five days of discovery. State officials and researchers have found these unapproved products can contain impurities, bacterial contamination, or inconsistent doses of active ingredient, and the settlement follows a similar case Tong brought against a Connecticut-based seller in 2025.

   ABC News / Good Morning AmericaRead the original at ABC News / Good Morning America (opens in a new tab)